News
New scientific discovery about the molecular mechanism of allergic reaction sheds light on the severity of peanut allergy
A single Ara h 2 allergen can bind simultaneously three copies of an IgE antibody commonly found in peanut allergic patients. This enables the formation of large allergen-IgE complexes on mast cell or basophil surfaces and contributes to the potency of Ara h 2 in triggering allergic reactions and highlights its role in anaphylaxis.
Enrolment completed in Phase 2 clinical study with DM-101PX, a novel immunotherapy for treating birch pollen allergy
Desentum, a clinical-stage biotechnology company developing novel allergen immunotherapies, today announced that its Phase 2 clinical study evaluating DM‑101PX for the treatment of birch pollen allergy has completed enrolment. 97 participants...
Kutsu Desentum Oy:n ylimääräiseen yhtiökokoukseen / Summons to Extraordinary General Meeting of Desentum Oy
Ylimääräinen yhtiökokous pidetään pidetään 3.2.2026 klo 13.00 alkaen /
Extraordinary General Meeting will be held on February 3rd, 2026, at 13.00 (EET)
Dosing started in Phase 2 clinical study with DM-101PX, a novel immunotherapy for treating birch pollen allergy
First trial participants have received their first doses in a Phase 2 clinical study, BASIT, evaluating DM-101PX for treatment of birch pollen allergy.
Phase 2 trial for birch pollen allergy treatment DM-101PX approved by Health Canada
The Canadian regulatory authority Health Canada has approved Desentum’s clinical trial application for a Phase 2 clinical study with DM-101PX, an investigational immunotherapeutic treatment for birch pollen allergy. Approximately 100 birch pollen...
Desentum to present clinical results of investigational birch pollen allergy vaccine DM-101PX and scientific discoveries about peanut allergy at the world’s largest allergy congress
All three abstracts submitted by Desentum have been accepted for oral presentations at the annual congress of the European Academy of Allergy and Clinical Immunology (EAACI) taking place in Glasgow, UK, on Jun 13–16, 2025. Two of the presentations...
Desentum reports strong safety and immunological data from Phase 1 clinical study with investigational birch pollen allergy vaccine DM-101PX
The short-course treatment was found to be safe and well tolerated in birch pollen allergic patients and to induce a very strong and sustained allergen-specific IgG4 response. DM-101PX-induced immunoglobulins were found to efficiently block IgE-mediated basophil activation endorsing the product’s potential to induce a protective immune response.
Ilmoitus osakkeiden siirtymisestä Desentum Oy:n osakkeenomistajille
Desentum Oy:n ("Yhtiö") yhtiöjärjestyksen 9 §:n mukaisesti osakkeenomistajille ilmoitetaan, että Exu Capital Oy on myynyt yhteensä 6000 B-osaketta ("Osakkeet") 2,00 euron osakekohtaiseen hintaan. Osakkeiden siirtymisestä on...
Pekka Mattila conferred as Honorary Doctor at the University of Eastern Finland
Pekka Mattila, CEO of Desentum was conferred as Honorary Doctor at the University of Eastern Finland on Jun 7, 2024. The Faculty of Science, Forestry and Technology stated the following: “In 2011, Pekka Mattila and researchers from the Department...
Desentum in the media
Here you can find links to articles about Desentum in international media. To see articles in Finnish media, change the language to Finnish from the upper right corner.